175 related articles for article (PubMed ID: 16369038)
1. Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen.
Polley R; Stager S; Prickett S; Maroof A; Zubairi S; Smith DF; Kaye PM
Infect Immun; 2006 Jan; 74(1):773-6. PubMed ID: 16369038
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells matured by inflammation induce CD86-dependent priming of naive CD8+ T cells in the absence of their cognate peptide antigen.
Maroof A; Beattie L; Kirby A; Coles M; Kaye PM
J Immunol; 2009 Dec; 183(11):7095-103. PubMed ID: 19917700
[TBL] [Abstract][Full Text] [Related]
3. Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects Kupffer cell-restricted antigen presentation to antigen-specific CD8 T cells.
Beattie L; Peltan A; Maroof A; Kirby A; Brown N; Coles M; Smith DF; Kaye PM
PLoS Pathog; 2010 Mar; 6(3):e1000805. PubMed ID: 20300603
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
5. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.
Sabur A; Bhowmick S; Chhajer R; Ejazi SA; Didwania N; Asad M; Bhattacharyya A; Sinha U; Ali N
Front Immunol; 2018; 9():18. PubMed ID: 29441060
[TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
[TBL] [Abstract][Full Text] [Related]
7. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
Anand S; Madhubala R
Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
[TBL] [Abstract][Full Text] [Related]
8. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
[TBL] [Abstract][Full Text] [Related]
9. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
10. TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis.
Karmakar S; Bhaumik SK; Paul J; De T
PLoS Pathog; 2012; 8(4):e1002646. PubMed ID: 22511870
[TBL] [Abstract][Full Text] [Related]
11. B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections.
Joshi T; Rodriguez S; Perovic V; Cockburn IA; Stäger S
PLoS Pathog; 2009 May; 5(5):e1000431. PubMed ID: 19436710
[TBL] [Abstract][Full Text] [Related]
12. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
13. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
14. Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects.
Vijayamahantesh ; Amit A; Dikhit MR; Singh AK; Venkateshwaran T; Das VNR; Das P; Bimal S
Microbes Infect; 2017 Jun; 19(6):358-369. PubMed ID: 28373107
[TBL] [Abstract][Full Text] [Related]
15. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
Basu R; Bhaumik S; Haldar AK; Naskar K; De T; Dana SK; Walden P; Roy S
Infect Immun; 2007 Dec; 75(12):5956-66. PubMed ID: 17908806
[TBL] [Abstract][Full Text] [Related]
16. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.
Ravindran R; Ali N
Curr Mol Med; 2004 Sep; 4(6):697-709. PubMed ID: 15357218
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis.
Santana DM; Borja-Cabrera GP; Paraguai de Souza E; Sturm NR; Palatnik de Sousa CB; Campbell DA
Mol Biochem Parasitol; 2002 Apr; 120(2):315-9. PubMed ID: 11897139
[No Abstract] [Full Text] [Related]
18. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
19. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
